![Christian Meyer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christian Meyer
Direttore operativo presso VectivBio AG
Posizioni attive di Christian Meyer
Società | Posizione | Inizio | Fine |
---|---|---|---|
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Direttore operativo | - | - |
Storia della carriera di Christian Meyer
Precedenti posizioni note di Christian Meyer
Società | Posizione | Inizio | Fine |
---|---|---|---|
Therachon Holding GmbH
![]() Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Direttore Tecnico/Scientifico/R&S | 01/11/2017 | 01/06/2019 |
UNIQURE N.V. | Direttore Tecnico/Scientifico/R&S | 01/09/2013 | 01/11/2017 |
Symphogen A/S
![]() Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Direttore Tecnico/Scientifico/R&S | 01/01/2006 | 01/01/2010 |
Consigliere Generale | 01/01/2006 | 01/01/2010 | |
Therachon AG | Corporate Officer/Principal | - | - |
VECTIVBIO HOLDING AG | Direttore operativo | 25/05/2021 | - |
Corporate Officer/Principal | 01/06/2019 | 25/05/2021 | |
RSPR Pharma AB
![]() RSPR Pharma AB Pharmaceuticals: MajorHealth Technology RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden. | Direttore Tecnico/Scientifico/R&S | 01/01/2006 | 01/01/2010 |
NOVO NORDISK A/S | Corporate Officer/Principal | - | - |
Formazione di Christian Meyer
University of Copenhagen | Doctorate Degree |
Statistiche
Distribuzione geografica
Svizzera | 5 |
Danimarca | 4 |
Paesi Bassi | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 4 |
Corporate Officer/Principal | 3 |
Chief Operating Officer | 2 |
Settori
Health Technology | 8 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
UNIQURE N.V. | Health Technology |
Aziende private | 6 |
---|---|
Symphogen A/S
![]() Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
RSPR Pharma AB
![]() RSPR Pharma AB Pharmaceuticals: MajorHealth Technology RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
VectivBio Holding AG
![]() VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Therachon Holding GmbH
![]() Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Health Technology |
Therachon AG | |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Christian Meyer
- Esperienza